KIT and gastrointestinal stromal tumor: Recently, it has been shown that PDGFRA mutant GIST display a more prominent immune cell pathway when compared to KIT mutant GIST, suggesting that immunotherapeutic strategies in GIST could be molecularly-driven (14).